Patents Assigned to EDITAS MEDICINE, INC.
  • NUCLEIC ACID MUTAGENESIS METHODS
    Publication number: 20200181666
    Abstract: The present disclosure relates to the manipulation of nucleic acids, and more particularly to systems and methods for nucleic acid mutagenesis.
    Type: Application
    Filed: March 29, 2018
    Publication date: June 11, 2020
    Applicant: Editas Medicine, Inc.
    Inventor: Barrett Ethan Steinberg
  • CRISPR/RNA-GUIDED NUCLEASE SYSTEMS AND METHODS
    Publication number: 20200155606
    Abstract: Genome editing systems, guide RNAs, dead guide RNAs, and CRISPR-mediated methods are provided for altering portions of a target nucleic acid.
    Type: Application
    Filed: November 8, 2019
    Publication date: May 21, 2020
    Applicant: Editas Medicine, Inc.
    Inventors: Edouard AUPEPIN DE LAMOTHE-DREUZY, Jack HEATH, Jennifer LEAH GORI, Luis BARRERA
  • CRISPR-related methods and compositions with governing gRNAs
    Patent number: 10640788
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Grant
    Filed: January 24, 2019
    Date of Patent: May 5, 2020
    Assignees: Editas Medicine, Inc., The Broad Institute Inc., Massachusetts Institute of Technology, University of Iowa Reseach Foundation
    Inventors: Feng Zhang, Deborah Palestrant, Beverly Davidson, Jordi Mata-Fink, Edgardo Rodriguez, Alexis Borisy
  • SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA
    Publication number: 20200056208
    Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
    Type: Application
    Filed: October 29, 2019
    Publication date: February 20, 2020
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
  • Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA
    Patent number: 10494649
    Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: December 3, 2019
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
  • Engineered Cas9 nucleases
    Patent number: 10428319
    Abstract: The present disclosure relates to Cas9 nuclease variants and methods of producing and using such variants.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: October 1, 2019
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Barrett Ethan Steinberg, Derek Cerchione
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS
    Publication number: 20190249157
    Abstract: Disclosed herein are genome editing systems and genetic constructs that targets a herpes simplex virus (HSV) viral gene comprising one Cas9 molecule, and a gRNA molecule, and compositions and cells comprising such genome editing systems and genetic constructs. Also provided are methods for using the genome editing systems, genetic constructs, compositions and cells for genome engineering (e.g., altering a HSV viral gene), and for preventing, treating or reducing HSV infection.
    Type: Application
    Filed: April 26, 2019
    Publication date: August 15, 2019
    Applicants: EDITAS MEDICINE, INC., DUKE UNIVERSITY
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot, Bryan R. Cullen
  • CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
    Publication number: 20190169639
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Application
    Filed: January 24, 2019
    Publication date: June 6, 2019
    Applicants: EDITAS MEDICINE, INC., THE BROAD INSTITUTE INC., THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, MASSACHUSETTS INSTITUITE OF TECHNOLOGY
    Inventors: Feng Zhang, Deborah Palestrant, Beverly Davidson, Jordi Mata-Fink, Edgardo Rodriguez, Alexis Borisy
  • GENETICALLY ENGINEERED CELLS AND METHODS OF MAKING THE SAME
    Publication number: 20190136230
    Abstract: Provided are CRIS PR/CAS-related methods, compositions and components for editing a target nucleic acid sequence, or modulating expression of a target nucleic acid sequence, and applications thereof in connection with cancer immunotherapy comprising adoptive transfer of engineered T cells or T cell precursors.
    Type: Application
    Filed: May 6, 2017
    Publication date: May 9, 2019
    Applicants: Juno Therapeutics, Inc., Editas Medicine, Inc.
    Inventors: Blythe SATHER, G. Grant WELSTEAD, David A. BUMCROT, Ari E. FRIEDLAND, Jon JONES, Morgan L. MAEDER, Chris NYE, Eugenio Marco RUBIO, Ruth SALMON
  • CRISPR/CAS-related methods and compositions for treating Leber's Congenital Amaurosis 10 (LCA10)
    Patent number: 10253312
    Abstract: CRISPR/CAS-related compositions and methods for treatment of Leber's Congenital Amaurosis 10 (LCA10) are disclosed.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: April 9, 2019
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Morgan Lee Maeder, David A. Bumcrot, Shen Shen
  • CRISPR-CPF1-RELATED METHODS, COMPOSITIONS AND COMPONENTS FOR CANCER IMMUNOTHERAPY
    Publication number: 20190062735
    Abstract: CRISPR/Cpf1-related compositions and methods for treatment of cancer.
    Type: Application
    Filed: September 4, 2018
    Publication date: February 28, 2019
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Gordon Grant Welstead, Hariharan Jayaram, Tongyao Wang, John Anthony Zuris, Christopher Borges
  • Crispr/Cas-Related Methods and Compositions for Treating Duchenne Muscular Dystrophy and Becker
    Publication number: 20190048337
    Abstract: CRISPR/CAS-related compositions and methods for treatment of DMD, BMD, or DCM type 3B are described.
    Type: Application
    Filed: September 29, 2017
    Publication date: February 14, 2019
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Patrick David Hsu, Morgan Lee Maeder, Penrose Odonnell, Joshua C. Tycko, Nicholas C. Huston
  • CRISPR-related methods and compositions with governing gRNAS
    Patent number: 10190137
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: January 29, 2019
    Assignees: Editas Medicine, Inc., The Broad Institute Inc., Massachusetts Institute of Technology, University of Iowa Research Foundation
    Inventors: Feng Zhang, Deborah Palestrant, Beverly Davidson, Jordi Mata-Fink, Edgardo Rodriguez, Alexis Borisy
  • METHODS FOR IMPROVING CRISPR/CAS-MEDIATED GENOME-EDITING
    Publication number: 20180298392
    Abstract: This application provides improved methods of editing the genome of a target cell. Cas9 molecules can be used to create a break in a genomic region of interest. To increase the likelihood that the break is repaired by homology-directed repair (HDR), the cell can be contacted with an HDR-enhancer. The cell may be, e.g., a human cell, a non-human animal cell, a bacterial cell, or a plant cell.
    Type: Application
    Filed: November 9, 2015
    Publication date: October 18, 2018
    Applicant: Editas Medicine, Inc.
    Inventor: Cecilia Cotta-Ramusino
  • SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA
    Publication number: 20180251792
    Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
    Type: Application
    Filed: May 15, 2018
    Publication date: September 6, 2018
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HERPES SIMPLEX VIRUS
    Publication number: 20180251770
    Abstract: CRISPR/CAS-related systems, compositions and methods for editing RS1, RL2, and/or LAT genes in human cells are described, as are cells and compositions including cells edited according to the same.
    Type: Application
    Filed: April 30, 2018
    Publication date: September 6, 2018
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell, David A. Bumcrot
  • CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HEPATITIS B VIRUS
    Publication number: 20180236103
    Abstract: CRISPR/CAS-related genome editing systems, compositions and methods for preventing and/or treating HBV infection are disclosed.
    Type: Application
    Filed: April 20, 2018
    Publication date: August 23, 2018
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Penrose O'Donnell
  • SYSTEMS AND METHODS FOR ONE-SHOT GUIDE RNA (ogRNA) TARGETING OF ENDOGENOUS AND SOURCE DNA
    Publication number: 20180201956
    Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
    Type: Application
    Filed: March 23, 2018
    Publication date: July 19, 2018
    Applicant: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
  • Systems and methods for one-shot guide RNA (ogRNA) targeting of endogenous and source DNA
    Patent number: 10006054
    Abstract: Engineered nucleic acids encoding genome editing system components are provided, as are engineered RNA-guided nucleases that include inserts encoded in part by cellular genomic or other sequences recognized by guide RNAs.
    Type: Grant
    Filed: March 23, 2018
    Date of Patent: June 26, 2018
    Assignee: EDITAS MEDICINE, INC.
    Inventors: Ari E. Friedland, Hariharan Jayaram, Barrett Ethan Steinberg
  • CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS
    Publication number: 20180127783
    Abstract: Disclosed herein are methods and compositions useful in targeting a payload to, or editing a target nucleic acid, where a governing gRNA molecule is used to target, optionally inactivate, a Cas9 molecule or a Cas9 molecule/gRNA complex.
    Type: Application
    Filed: November 29, 2017
    Publication date: May 10, 2018
    Applicants: EDITAS MEDICINE, INC., THE BROAD INSTITUTE INC., THE UNIVERSITY OF IOWA RESEARCH FOUNDATION, MASSACHUSETTS INSTITUITE OF TECHNOLOGY
    Inventors: Feng ZHANG, Deborah PALESTRANT, Beverly DAVIDSON, Jordi MATA-FINK, Edgardo RODRIGUEZ, Alexis BORISY